The following posters will be presented: IPH5201 as monotherapy or in combination with durvalumab in advanced solid tumors (
Abstract Number: 472
Session
Session Time: 8 December, 12:30-13:15
Location:
Presenter: Dr.
Combination of IPH5201, a block antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale
Abstract Number: 384
Session
Session Time: 8 December, 12:30-13:15
Location:
Presenter:
A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES) (Institut Paoli-Calmettes)
Abstract Number: 290
Session
Session Time: 8 December, 12:30-13:15
Location:
Presenter: Dr.
The posters will be available on the Publications section of Innate's website following the meeting.
About IPH5201
IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment. It is being developed in partnership with
A first-in-human, multi-centre, non-randomised, open-label, phase 1 study (NCT04261075) sponsored by
A Phase 2 clinical trial conducted by Innate in lung cancer is in planning.
About IPH5301
IPH5301 is a CD73-blocking monoclonal antibody currently in an investigator-sponsored Phase 1 trial in collaboration with the Institut Paoli-Calmettes (IPC) and Oncodistinct Network.
By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.
Contact:
Tel: +33 (0)4 30 30 30 30
(C) 2022 Electronic News Publishing, source